Search
Ubrogepant
go.drugbank.com/drugs/DB15328ApprovedInvestigational[erenumab], [fremanezumab], [galcanezumab]) have also been approved in recent years.[A189207] Ubrogepant was approved by Health Canada on November 10, 2022. … [L10926] It was approved by the FDA on December 23, 2019, and is the first oral calcitonin gene-related peptide (CGRP) receptor antagonist approved for the acute treatment of migraine.
Givosiran
go.drugbank.com/drugs/DB15066Approvedinvolved non-therapeutic measures (e.g. trigger avoidance), intravenous [hemin] for the treatment of attacks, and liver transplantation in refractory cases. … [L10202] It is manufactured by Alnylam Pharmaceuticals and was first approved for use in the United States in November 2019 for the treatment of adults with acute hepatic porphyria, a genetic disorder
Carbetocin
go.drugbank.com/drugs/DB01282ApprovedInvestigationalIt is an analogue of oxytocin, and its action is similar to that of oxytocin -- it causes contraction of the uterus.
Products: Carbetocin Aguettant 100 Mikrogramm/ml Injektionslösung in einer FertigspritzeMumps virus strain B level jeryl lynn live antigen
go.drugbank.com/drugs/DB10316ApprovedInvestigationalIt is an active immunization against mumps, which is a common childhood disease.
Mixtures: Priorix Pulver in einer Durchstechflasche und Lösungsmittel in einer Fertigspritze zur Herstellung einer Injektionslösung, Priorix - Tetra Pulver in einer Durchstechflasche und Lösungsmittel in einer Fertigspritze zur Herstellung einer InjektionslösungPramlintide
go.drugbank.com/drugs/DB01278ApprovedInvestigationalIt is derived from amylin, a hormone that is released into the bloodstream, in a similar pattern as insulin, after a meal. Like insulin, amylin is deficient in individuals with diabetes.
Categories: Drugs Used in DiabetesUlobetasol
go.drugbank.com/drugs/DB00596Approved[L15047,L15052,L15102] Ulobetasol was granted FDA approval on 17 December 1990.[L15047] … [A215597] Due to its high potency, it is mainly prescribed in the treatment of severe plaque psoriasis and corticosteroid responsive dermatoses.
Tetrabenazine
go.drugbank.com/drugs/DB04844ApprovedFDA approved on August 15, 2008. … A drug formerly used as an antipsychotic but now used primarily in the symptomatic treatment of various hyperkinetic disorders.
Estradiol cypionate
go.drugbank.com/drugs/DB13954ApprovedVet approvedin various tissues and organs such as the breasts, uterus, ovaries, skin, prostate, bone, fat, and brain. … Estradiol cypionate is commercially available as Depo-Estradiol, an intramuscular depot injection used for the treatment of moderate to severe vasomotor symptoms associated with menopause and for the treatment
Lebrikizumab
go.drugbank.com/drugs/DB11914ApprovedInvestigational[L49404] Lebrikizumab was also approved by the FDA on September 13, 2024.[L51379] … [A262874,A262879] On November 17, 2023, lebrikizumab was approved by the EMA under the brand name EBGLYSS for the treatment of moderate-to-severe atopic dermatitis in adult and adolescent patients 12
Cabergoline
go.drugbank.com/drugs/DB00248ApprovedInvestigationalCabergoline possesses potent agonist activity on dopamine D2 receptors. … Cabergoline, an ergot derivative, is a long-acting dopamine agonist and prolactin inhibitor. It is used to treat hyperprolactinemic disorders and Parkinsonian Syndrome.
Synonyms: (8R)-6-allyl-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)ergoline-8-carboxamide, (8β)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-ergoline-8-carboxamide